Free Trial

Fate Therapeutics (FATE) News Today

→ It's time to ween off Chinese lithium! (From Smallcaps Daily) (Ad)
Free FATE Stock Alerts
$3.86
+0.18 (+4.89%)
(As of 05:12 PM ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends
June 9 at 9:16 AM | marketbeat.com
Vestal Point Capital LP Buys New Position in Fate Therapeutics, Inc. (NASDAQ:FATE)
Vestal Point Capital LP bought a new stake in Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 1,290,000 shares of the biopharmaceutical company's stock, valued at approximately $
June 4, 2024 | globenewswire.com
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
June 4, 2024 | americanbankingnews.com
Fate Therapeutics, Inc. (NASDAQ:FATE) Short Interest Update
June 3, 2024 | marketbeat.com
Short Interest in Fate Therapeutics, Inc. (NASDAQ:FATE) Decreases By 6.0%
Fate Therapeutics, Inc. (NASDAQ:FATE - Get Free Report) was the target of a significant decline in short interest during the month of May. As of May 15th, there was short interest totalling 20,810,000 shares, a decline of 6.0% from the April 30th total of 22,140,000 shares. Based on an average daily trading volume, of 2,590,000 shares, the days-to-cover ratio is currently 8.0 days.
May 29, 2024 | globenewswire.com
Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference
May 28, 2024 | finance.yahoo.com
New Memoir "Echoes of Fate: From Birth to the Last Heartbeats" Captures the Essence of Human Existence and Legacy
May 17, 2024 | marketbeat.com
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Rating of "Hold" by Brokerages
Shares of Fate Therapeutics, Inc. (NASDAQ:FATE - Get Free Report) have earned a consensus rating of "Hold" from the fourteen research firms that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, ten have issued a hold r
May 16, 2024 | marketbeat.com
Fate Therapeutics, Inc. (NASDAQ:FATE) Short Interest Up 17.0% in April
Fate Therapeutics, Inc. (NASDAQ:FATE - Get Free Report) was the recipient of a significant growth in short interest in the month of April. As of April 30th, there was short interest totalling 22,140,000 shares, a growth of 17.0% from the April 15th total of 18,920,000 shares. Based on an average daily trading volume, of 2,620,000 shares, the days-to-cover ratio is currently 8.5 days.
May 16, 2024 | markets.businessinsider.com
Fate Therapeutics: Advancements and Differentiation in Autoimmune and Cancer Therapies Support Buy Rating
May 16, 2024 | marketbeat.com
Fate Therapeutics (NASDAQ:FATE) PT Lowered to $5.00
HC Wainwright dropped their price target on shares of Fate Therapeutics from $7.00 to $5.00 and set a "neutral" rating for the company in a research note on Thursday.
May 14, 2024 | markets.businessinsider.com
Hold Rating on Fate Therapeutics Amid Pending Clinical Data and Strategic Pipeline Focus
May 13, 2024 | seekingalpha.com
Fate Therapeutics, Inc. (FATE) Q1 2024 Earnings Call Transcript
May 13, 2024 | finance.yahoo.com
Fate Therapeutics, Inc. (NASDAQ:FATE) Q1 2024 Earnings Call Transcript
May 11, 2024 | marketbeat.com
Monaco Asset Management SAM Acquires 335,284 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE)
Monaco Asset Management SAM increased its holdings in shares of Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) by 18.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,183,228 shares of the biopharmaceutical compa
May 11, 2024 | finance.yahoo.com
Fate Therapeutics First Quarter 2024 Earnings: Revenues Beat Expectations, EPS In Line
May 11, 2024 | marketbeat.com
StockNews.com Downgrades Fate Therapeutics (NASDAQ:FATE) to Sell
StockNews.com downgraded shares of Fate Therapeutics from a "hold" rating to a "sell" rating in a research note on Friday.
May 10, 2024 | marketbeat.com
Fate Therapeutics (NASDAQ:FATE) Issues Quarterly Earnings Results, Hits Expectations
Fate Therapeutics (NASDAQ:FATE - Get Free Report) issued its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.47) EPS for the quarter, meeting analysts' consensus estimates of ($0.47). The business had revenue of $1.93 million for the quarter, compared to analysts' expectations of $0.80 million. Fate Therapeutics had a negative net margin of 253.30% and a negative return on equity of 38.17%. During the same period last year, the business earned ($0.19) earnings per share.
May 10, 2024 | marketbeat.com
Canaccord Genuity Group Lowers Fate Therapeutics (NASDAQ:FATE) Price Target to $9.00
Canaccord Genuity Group reduced their price objective on Fate Therapeutics from $11.00 to $9.00 and set a "buy" rating for the company in a research note on Friday.
May 10, 2024 | markets.businessinsider.com
Fate Therapeutics: Strategic Shifts Prompt Hold Rating Amidst Awaited Clinical Results
May 10, 2024 | finance.yahoo.com
Fate Therapeutics Inc (FATE) Q1 2024 Earnings: Mixed Financial Performance Amid Clinical ...
May 9, 2024 | investorplace.com
FATE Stock Earnings: Fate Therapeutics Beats EPS, Beats Revenue for Q1 2024
May 9, 2024 | sfgate.com
Fate Therapeutics: Q1 Earnings Snapshot
May 9, 2024 | msn.com
Fate Therapeutics GAAP EPS of -$0.47 in-line, revenue of $1.93M beats by $0.67M
May 9, 2024 | globenewswire.com
Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
May 9, 2024 | globenewswire.com
Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program
May 8, 2024 | markets.businessinsider.com
Here's what to expect from Fate Therapeutics's earnings
May 8, 2024 | msn.com
Fate Therapeutics Q1 2024 Earnings Preview
May 8, 2024 | marketbeat.com
Fate Therapeutics, Inc. to Post Q1 2024 Earnings of ($0.42) Per Share, Wedbush Forecasts (NASDAQ:FATE)
Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) - Analysts at Wedbush lifted their Q1 2024 earnings per share (EPS) estimates for Fate Therapeutics in a note issued to investors on Monday, May 6th. Wedbush analyst D. Nierengarten now expects that the biopharmaceutical company will earn ($0.42
May 7, 2024 | marketbeat.com
Fate Therapeutics (FATE) Set to Announce Quarterly Earnings on Thursday
Fate Therapeutics (NASDAQ:FATE) will be releasing earnings after the market closes on Thursday, May 9, Zacks reports.
May 6, 2024 | marketbeat.com
Fate Therapeutics (NASDAQ:FATE) Earns Neutral Rating from Wedbush
Wedbush reaffirmed a "neutral" rating and issued a $7.00 target price on shares of Fate Therapeutics in a research report on Monday.
May 6, 2024 | finance.yahoo.com
Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2024 Financial Results and Operational Updates
May 3, 2024 | globenewswire.com
Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting
May 2, 2024 | finance.yahoo.com
AskBio Announces Nine Presentations at American Society of Gene and Cell Therapy 27th Annual Meeting 2024
May 2, 2024 | markets.businessinsider.com
Barclays Reaffirms Their Buy Rating on Iovance Biotherapeutics (IOVA)
April 29, 2024 | seekingalpha.com
Fate Therapeutics: As Its Rally Fizzles, We May Be Near The Bottom
April 27, 2024 | thestreet.com
Struggling retail chain shares Chapter 11 bankruptcy fate
April 26, 2024 | msn.com
Grandmother gets new lease on life from heart pump, pig kidney
April 26, 2024 | msn.com
Biden campaign says it will keep using TikTok - despite president signing law that could ban app
April 26, 2024 | yahoo.com
Orlando police fulfill 4-year-old boy's dream of being an officer
April 25, 2024 | marketbeat.com
Federated Hermes Inc. Sells 601,672 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE)
Federated Hermes Inc. lessened its position in shares of Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) by 24.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,849,872 shares of the biopharmaceutical company'
April 23, 2024 | nytimes.com
Our Reporter on the Fate of a Gazan University Class
April 23, 2024 | marketbeat.com
Fate Therapeutics' (FATE) "Neutral" Rating Reaffirmed at Wedbush
Wedbush reissued a "neutral" rating and issued a $7.00 target price on shares of Fate Therapeutics in a report on Tuesday.
April 22, 2024 | globenewswire.com
Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting
April 19, 2024 | marketbeat.com
Fate Therapeutics (NASDAQ:FATE) Shares Down 5.4%
Fate Therapeutics (NASDAQ:FATE) Shares Down 5.4%
April 18, 2024 | msn.com
Fate Therapeutics files to sell 3.64M shares for holders
April 17, 2024 | marketbeat.com
Fate Therapeutics (NASDAQ:FATE) Shares Gap Up to $5.38
Fate Therapeutics (NASDAQ:FATE) Shares Gap Up to $5.38
April 15, 2024 | marketbeat.com
Fate Therapeutics, Inc. (NASDAQ:FATE) Sees Significant Growth in Short Interest
Fate Therapeutics, Inc. (NASDAQ:FATE - Get Free Report) saw a significant increase in short interest in March. As of March 31st, there was short interest totalling 16,490,000 shares, an increase of 25.3% from the March 15th total of 13,160,000 shares. Approximately 19.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 2,860,000 shares, the short-interest ratio is presently 5.8 days.
April 14, 2024 | marketbeat.com
Fate Therapeutics, Inc. (NASDAQ:FATE) Position Trimmed by Vanguard Group Inc.
Vanguard Group Inc. trimmed its holdings in shares of Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) by 7.0% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 10,908,351 shares of the biopharmaceutical company's stock after selli
April 11, 2024 | marketbeat.com
Fate Therapeutics' (FATE) Hold Rating Reiterated at Needham & Company LLC
Needham & Company LLC reiterated a "hold" rating on shares of Fate Therapeutics in a research note on Thursday.
April 10, 2024 | msn.com
A promising target for new RNA therapeutics now accessible
Get Fate Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for FATE and its competitors with MarketBeat's FREE daily newsletter.

No Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for Free (Ad)

Optimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analysis meets hedge fund-level market foresight!

TRY "INVESTING IDEAS" TODAY

FATE Media Mentions By Week

FATE Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

FATE
News Sentiment
▼
1.37

0.76
▲
Average
Medical
News Sentiment

FATE News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

FATE Articles
This Week
▼
4

3
▲
FATE Articles
Average Week

Get Fate Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for FATE and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

Related Companies:
Headlines Tools:
This page (NASDAQ:FATE) was last updated on 6/10/2024 by MarketBeat.com Staff

From Our Partners
It's time to ween off Chinese lithium!
As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...
Smallcaps Daily | Sponsored
Top 5 Tech Stocks to Buy for 2024
The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...
Daily Market Alerts | Sponsored
Top 5 AI Stocks to Buy for 2024
The electric vehicle boom is accelerating – and fast.
Market Moving Trends | Sponsored
No Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for Free
Optimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...
Hedgeye | Sponsored
Moonshot Coins for the Current Crypto Run
Did you see bitcoin crossed $70k again? Don't miss the next bull run. Because while Bitcoin and Ethereum s...
Crypto 101 Media | Sponsored
The Only Energy Play You Should Be Looking At
Open AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...
Wealthpin Pro | Sponsored
RSVP: Charles Payne’s Cash Flow Workshop
Did you know you could "cash flow" the stocks in your portfolio? Without selling a single share of stock? ...
Unstoppable Prosperity | Sponsored
AI's Next Magnificent Seven
The Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.
The Oxford Club | Sponsored